Information Provided By: 
Fly News Breaks for September 24, 2015
ALXN
Sep 24, 2015 | 07:24 EDT
Oppenheimer expects Alexion to report better than expected revenue over the next 12-18 months, driven by the launches of its Strensiq and Kanuma drugs. The firm thinks that the drug launches carry little risk, and it does not expect the company to be affected by pricing pressures. It keeps a $228 price target and Outperform rating on the shares.
News For ALXN From the Last 2 Days
There are no results for your query ALXN
